For example, in HER2-positive breast cancer, the presence of high TILs may enhance the effectiveness of trastuzumab, and ongoing research explores combining targeted therapies with immunotherapy to further improve outcomes.[42]. Here, ERBB2 is linked to breast carcinoma.